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IL-1𝛽 is one of the main proinflammatory cytokines that regulates a broad range of immune responses and also participates in
several physiological processes. The canonical production of IL-1𝛽 requires multiprotein complexes called inflammasomes. One of
the most intensively studied inflammasome complexes is the NLRP3 inflammasome. Its activation requires two signals: one signal
“primes” the cells and induces the expression of NLRP3 and pro-IL-1𝛽, while the other signal leads to the assembly and activation
of the complex. Several stimuli were reported to function as the second signal including reactive oxygen species, lysosomal rupture,
or cytosolic ion perturbation. Despite very intensive studies, the precise function and regulation of the NLRP3 inflammasome are
still not clear. However, many chronic inflammatory diseases are related to the overproduction of IL-1𝛽 that is mediated via the
NLRP3 inflammasome. In this review, we aimed to provide an overview of studies that demonstrated the effect of plant-derived
natural compounds on NLRP3 inflammasome-mediated IL-1𝛽 production. Although many of these studies lack the mechanistic
explanation of their action, these compounds may be considered as complementary supplements in the treatment of chronic
inflammatory diseases, consumed as preventive agents, and may also be considered as molecular tools to study NLRP3 function.
1. Introduction
Inflammation is an important host response triggered by
invading pathogens or damaged tissues, a response that is
aimed at diluting or destroying the pathogens or isolating the
involved site. Moderate inflammatory response contributes
to the host defense by removing pathogens or aiding in
the repair of damaged tissue. However, uncontrolled or
prolonged inflammation may promote further tissue damage
and could lead to serious disorders due to the overproduction
of inflammatory cytokines.
Among inflammatory mediators, IL-1𝛽 is a master reg-
ulatory cytokine, functioning at several levels of immune
responses, such as activation of cells to produce other inflam-
matory cytokines and chemokines, induction of endothe-
lial cells to express cell membrane adhesion molecules, or
assisting in the polarization of human Th17 cells [1–3].
Furthermore, it also participates in a variety of physiological
processes, such as the regulation of synaptic plasticity and
memory processes, in addition to participating in pain
development [4–7].
The production of IL-1𝛽 requires a multiprotein complex
called inflammasome. One of the most intensively studied
inflammasomes is the NLRP3 inflammasome that contains
NLRP3 sensor, ASC adaptor, and caspase-1 protease [8].
The presence of NLRP3 inflammasome has been shown not
only in immunocompetent cells but also in cells respon-
sible for various physiological functions, such as muscle
cells, neurons, or endocrine cells. Upon stimulation, NLRP3
inflammasome components assemble into large cytoplasmic
complexes, and the activation of caspase-1 eventually leads
to the maturation and secretion of IL-1𝛽. Besides cytokine
production, NLRP3 inflammasome activation may also be
accompanied by caspase-1-mediated rapid cell death, which
is known as pyroptosis [9].
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Figure 1: Basic mechanisms of NLRP3 inflammasome activation.
2. Mechanism of NLRP3 Inflammasome
Activation
NLRP3 inflammasome can be activated by a broad range of
stimuli that belong either to pathogen-associated molecular
patterns (PAMPs) released during viral, bacterial, fungal, or
protozoa infection [10–13] or to danger-associated molecular
patterns (DAMPs) of endogenous or exogenous origin, like
extracellular ATP, reactive oxygen species (ROS), choles-
terol, monosodium urate (MSU) crystals, amyloid beta (A𝛽)
plaques, silica, or asbestos [14–20] (Figure 1).
Due to the multiple functions of IL-1𝛽, production of
this cytokine is tightly regulated, requiring two signals. The
first signal, called “priming,” is mediated through PAMPs
recognized by specific receptors like TLRs, activating signal
transduction pathways that induce the expression of the
inflammasome components as well as that of the inactive
cytokine precursor pro-IL-1𝛽. Signaling pathways through
NF𝜅B, p38, and ERK1 have all been associated with the
expression of NLRP3 and pro-IL-1𝛽 [21–23]. The second
signal, provided by DAMPs or PAMPs, leads to the assembly
of the inflammasome complex that is followed by activation
of caspase-1 and the cleavage and secretion of active IL-
1𝛽 [24, 25]. Considering the diversity of the second signals
sensed by NLRP3, it is highly unlikely that NLRP3 is capable
of interacting directly with chemically different activators.
It is more likely that NLRP3 senses a general signal that
induces the sequential events of inflammasome activation.
Several cellular mechanisms were reported as requirements
for activation, including intracellular release of oxidized
mitochondrial DNA (mtDNA), increased intracellular Ca2+
concentration, decreased intracellular cAMP level, or pore
formation by bacterial toxins [26–28]. Common cellular
events are assumed to be critical for the inflammasome
activation, including ROS formation, potassium (K+) efflux,
and cathepsin B leakage from lysosomes [29]. However,
due to the controversial results published in the field, the
precise mechanism that mediates NLRP3 inflammasome
activation is still not known. It is conceivable that more
than one single requirement needs to be fulfilled, and these
requirements may depend on the activating stimuli, also the
per se characteristics of the stimulated cell.
2.1. Reactive Oxygen Species. Several NLRP3 inflammasome
activating stimuli like nigericin or ATP induce oxidative
stress and the production of intracellular ROS [15]. The
source of ROS is still unclear, as some of the studies
reported the role of NADPH oxidase in ROS generation [30],
while other studies proved that mitochondrial dysfunction
or ER stress leads to ROS production. As a consequence
of mitochondrial dysfunction, oxidized mtDNA is released
which can activate NLRP3 inflammasome [26], eventually
leading to IL-1𝛽 production. It was also shown that, in
case of increased cytoplasmic ROS, reduced thioredoxin
(TRX) becomes oxidized and dissociates from thioredoxin
binding protein (TXNIP) that in turn binds to and acti-
vates NLRP3. It was also shown that the expression of
TXNIP is upregulated during ER stress, which also induces
NLRP3 activation [31]. During oxidative stress, misfolded
proteins accumulate, which are sensed by the ERmembrane-
bound inositol-requiring enzyme 1 (IRE1𝛼) and protein
kinase RNA-like endoplasmic reticulum kinase (PERK).
In turn, they initiate ER stress response, activate NF𝜅B
pathways, and induce the upregulation of TXNIP expres-
sion [32]. The role of nuclear factor- (rythroid-derived 2)
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like 2 (Nrf2) transcription factor-mediated antioxidant sig-
naling pathway has also been reported as a negative regulator
of NLRP3 inflammasome, as disruption of Nrf2 leads to
increased production of IL-1𝛽 [33]. Recent works highlight
the importance ofmetabolic changes such as in glycolysis and
oxidative phosphorylation that accompany cell activation and
influence ROS production [34, 35].Moreover, ROS influences
signal transduction pathways such as NF𝜅B; thus, besides
NLRP3 inflammasome activation, it is also thought to play
a role in the “priming” step [36].
2.2. Ion Flux and Perturbation. Perturbation of cytosolic ion
concentration, such as K+ and Ca2+, is a common result
of several NLRP inflammasome activating stimuli, as many
activators were shown to directly induce ion fluxes. Nigericin
or the activation of ATP-sensitive P2X7 receptor induces
rapid efflux of K+ [37–39], and K+ efflux has been proven
to act as a common signal to trigger NLRP3 inflammasome
activation [40]. Furthermore, several pore forming toxins
result in an increased intracellular Ca2+ that triggers NLRP3
activation [41]. Nevertheless, changes in intracellular ion
concentration would also stimulate other inflammasome
complexes, which argues against ion flux as the exclusive
cause for NLRP3 inflammasome activation.
2.3. Lysosomal Rupture and Cathepsin B Release. Destabi-
lization of the acidic lysosomal compartment and release of
lysosomal protease cathepsin B into the cytoplasm during
phagocytosis of large particles or crystals, such as silica,
asbestos, uric acid, or beta-amyloids, have also been impli-
cated in the activation of the NLRP3 inflammasome [42].
Furthermore, phagocytosis could also induce K+ efflux.
Additionally, lysosomes contain high concentration of Ca2+,
and lysosomal rupture results in the release of Ca2+ into
the cytosol, triggering further Ca2+ release from the ER.
However, the molecular details and connections of these
events are not yet clarified. In conclusion, although NLRP3
inflammasome is themost intensively studied inflammasome
complex, it is still unclear which mechanisms are responsible
for its activation.
2.4. Mitochondrial Dysfunction. In response to infection or
endogenous stimuli, the perturbation of intracellular ROS,
K+, or lysosomal stability leads to mitochondrial dysfunction
and to the release of mitochondrial DAMPs such as mtDNA,
cardiolipin, or dynamin-related protein 1 (Drp1) [43]. It
was shown that due to increased mtROS level, released
mtDNA is oxidized and activatesNLRP3 inflammasome [26].
Cardiolipin is a non-bilayer-forming phospholipid found
in bacteria and in the inner mitochondrial membrane of
eukaryotes, and its translocation from the inner membrane
to the outer membrane was shown to activate NLRP3 inflam-
masomedownstreamofmtROS [44]. It was also reported that
GTPaseDrp1, that is needed for the fragmentation and aggre-
gation of mitochondria, also induces NLRP3 inflammasome
activation and IL-1𝛽 secretion in response to VSV infection
but not to ATP or nigericin [45]. Moreover, mitofusin, an
outer mitochondrial GTPase that regulates mitochondrial
fusion, was also described as an NLRP3 activator during
viral infection [46]. Recently, it was described that the
mitochondrial antiviral signaling protein (MAVS) located in
themitochondrialmembranemediating interferon responses
also induces NLRP3 inflammasome activation [47]. These
reports demonstrate that the mitochondrion is a complex
regulator of cytosolic homeostasis and a central platform for
NLRP3 inflammasome activation.
2.5. Autophagy. Autophagy is an evolutionarily conserved
mechanism to maintain cellular homeostasis by selectively
eliminating damaged or aging organelles, microbes, and
ubiquitinated proteins, through the formation of autophago-
somes and using lysosomal degradation. Lines of evi-
dence show that autophagy suppresses organelle stress-
induced activation of NLRP3 inflammasome. Furthermore,
it was reported that inducers of autophagy also induce
the autophagosomal engulfment of IL-1𝛽 and its lysosomal
degradation [48]. It was also shown that damaged mitochon-
dria accumulate in autophagy-deficient macrophages that in
turn lead to increased intracellular ROS and to the release of
mtDNA [49].
2.6. Spatial Location of NLRP3. Originally, it was shown
that activated NLRP3 inflammasome localizes to the mito-
chondria. However, recently, it was described that during
inflammasome activation ER-associated NLRP3 colocalizes
with the mitochondria-associated ASC to the perinuclear
space via a microtubule-mediated organelle transport. It was
shown that, upon cell activation, the decreased intracellular
NAD+ level leads to the inhibition of sirtuin 2 (SIRT2)
deacetylase, resulting in the accumulation of acetylated alfa-
tubulin triggering a dynein-dependent transport of mito-
chondria to the perinuclear region, into the close proximity
to the ER [50].
3. NLRP3 Inflammasome and Related Diseases
Understanding the steps and mechanism of NLRP3 inflam-
masome activation would be of crucial importance for
the treatment of several diseases in which the inflamma-
some complex has been implicated. By producing IL-1𝛽
inflammatory cytokine and inducing pyroptosis, the primary
function of NLRP3 inflammasome is to protect the host
from invading microorganisms [78]. However, nonmicrobial
compounds of either endogenous (self-derived) or exogenous
(environmental) origin are also effective inducers of NLRP3
inflammasome activation and lead to sterile inflammation,
allergic responses, or other forms of inflammation [79]. For
example, studies have shown that NLRP3 may be implicated
in Alzheimer’s disease, suggesting that misfolded A𝛽 pro-
teins form aggregates that lead to the activation of NLRP
inflammasome [80, 81]. In gout, MSU crystals from purine
degradation form deposits in different tissues and specif-
ically activate NLRP3 inflammasome [14]. Environmental
particulates such as inhaled asbestos and silica also activate
NLRP3 inflammasome, and the high concentration of IL-
1𝛽 is involved in the development of asbestosis and silico-
sis, two progressive pulmonary diseases leading to fibrosis
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[16, 82]. NLRP3 inflammasome has also been related to
allergic responses to a variety of allergens, such as aluminum,
dust mite, or ragweed pollen; however, the molecular details
of these responses are still not clear [83–85].
Other studies associated NLRP3 inflammasome function
withmetabolic syndrome and type 2 diabetes, as NLRP3 defi-
cient mice were protected from high fat diet- (HFT-) induced
inflammation, glucose intolerance, insulin resistance, and
obesity [86, 87].
The dysregulated production of IL-1𝛽 by the NLRP3
inflammasome is the main reason for the development of
Cryopyrin-Associated Periodic Syndromes (CAPS) which is
caused by a mutation in NLRP3 gene. CAPS is an autoin-
flammatory disorder rather than an autoimmune one, as
symptoms aremediated by the innate immune system,mainly
by monocytes and macrophages that produce huge amount
of IL-1𝛽. Behcet’s disease (BD) is another chronic autoin-
flammatory disorder of unknown etiology, and increased
IL-1𝛽 production has been noted as a central player in the
pathogenesis of this disease. Studies demonstrated increased
ROS production and, consequently, increased NLRP3 func-
tion in these patients, suggesting an important role forNLRP3
inflammasome in mediating cytokine production [88]. In
addition to autoinflammatory diseases, NLRP3 inflamma-
some function has also been implicated in the development
of autoimmune diseases like rheumatoid arthritis (RA) [89].
RA is a common inflammatory disease affecting small joints,
and our knowledge about its pathogenesis is still incomplete.
Nevertheless, elevated levels of IL-1𝛽 and high expression of
NLRP3 were detected from the serum and synovial tissue as
well as in macrophages of RA patients [90].
At present, the role of NLRP3 inflammasome and IL-
1𝛽 in cancer is highly controversial. The microenvironment
of tumors is characterized by an inflammatory milieu that
helps tumor survival with growth hormones, endothelial
activation, and angiogenesis that leads to metastasis accom-
panied by immune suppression. IL-1𝛽 participates in each of
these mechanisms by stimulating the expression of TNF𝛼,
MMPs, VEGF, ICAM-1, VCAM, and so forth. Cancer cells,
like melanoma or myeloma, as well as tumor-associated
macrophages and dendritic cells, were shown to contribute to
the IL-1𝛽 production that helps survival and growth of tumor
cells; furthermore, excessive production of IL-1𝛽 can recruit
immunosuppressive cells like myeloid-derived suppressors
cells (MDSCs) [91]. On the other hand, it was also shown that
NLRP3-induced IL-1𝛽 production boosts T cell function in
patients receiving chemotherapy [92].
The classical medical approach to treating the above-
mentioned diseases involves the use of synthetic drugs devel-
oped against individual elements of the signaling pathway,
the IL-1𝛽 cytokine, or the IL-1𝛽 receptor, as reviewed in
Ozaki et al., 2015 [93]. However, today, in the health-cautious
life era, the use of botanical and natural compounds has
gained popularity. While a few decades ago the use of natural
compounds was based exclusively on empirical experiences,
today, with the highly developed molecular biological, high
throughput methods, many molecular elements of their
action have already been identified. However, fundamental
questions remain to be answered, including bioavailability,
effective doses, body concentrations, cross-reactivity, half-
life and degradation, and synergistic effect of compounds
as well as carefully designed clinical trials. The aim of the
present review is to provide an overview of these plant-
derived natural compounds that would support the use of
medicinal plants (Figure 2). As a variety of compounds can
influence inflammasome activation and function, we have
focused on natural compounds that have been in long term
use in traditional medicine; therefore, their safety and overall
effect are mostly established. However, these compounds
typically influence a multitude of pathways, and the exact
molecular mechanisms of their beneficial actions are not
completely clarified (Table 1).
4. Natural Compounds Affecting NLRP3
Inflammasome Activation
4.1. Aloe vera. Aloe vera is a medical plant used traditionally
in diverse therapeutic applications. The gel of Aloe vera
has been reported to stimulate wound-healing and skin
hydration, induce hematopoiesis, and possess antidiabetic,
anticarcinogenic, antimicrobial, and antioxidant as well as
anti-inflammatory activities. Over 75 active components have
already been identified in Aloe vera leaf gels [94], and
some of them have been implicated as immunomodulatory
compounds based on animal studies. In amouse sepsismodel
and in a human colorectal mucosa model, treatment with
Aloe vera significantly inhibited the elevation of TNF𝛼, IL-
6, and IL-1𝛽 levels [95, 96]. Studying human THP-1 cells
and human monocyte-derived macrophages, it was found
that Aloe vera treatment significantly reduced LPS-induced
IL-1𝛽 production [51]. Aloe vera inhibited the expression
of pro-IL-1𝛽, NLRP3, and caspase-1 as well as that of the
P2X7 receptor in the LPS-induced primary macrophages.
Furthermore, LPS-induced activation of signaling pathways,
such as NF-𝜅B, p38, JNK, and ERK, were inhibited by Aloe
vera in these cells [51].
Aloe emodin is an anthraquinone, present naturally in
Aloe leaves. It has been shown to promote natural killer cell
activity andmacrophage phagocytosis in tumor [97]. Emodin
itself appears to have some protective effect in the inflamma-
tory response. Recently, it was shown that emodin attenuated
nigericin-, ATP-, and silica-induced IL-1𝛽 secretion from
LPS-activated murine bone marrow-derived macrophages
(BMDMs). It was also shown that mice treated intraperi-
toneally with emodin showed higher survival rates than con-
trol mice injected with LPS alone, indicating that emodin can
ameliorate the severity of NLRP3 inflammasome-mediated
disease symptoms in vivo [52]. However, further molecular
details of the inhibitory effect are yet to be discovered.
4.2. Curcumin. Curcumin is a lipid soluble polyphenol, a
yellow pigment isolated from the rhizomes of Curcuma longa
(turmeric), but also found in other plants like ginger. It is
widely used in food coloring and flavoring and it is also added
to cosmetics. It has gained attention in recent years for its
multiple pharmacological properties, being antioxidant, anti-
inflammatory, and antimicrobial, as well as for its therapeutic






































































Figure 2: Chemical structure of natural compounds influencing NLRP3 inflammasome activation.
potential in cancer, autoimmune, metabolic, pulmonary,
cardiovascular, and neurological diseases (reviewed in [98]).
Brain ischemia is known to induce ER stress and inflam-
matory responses leading to neuronal damage [99, 100]. In
a recent study, glucose deprivation or hypoxia was reported
to strongly induce the production of glutamate and IL-1𝛽 in
mouse hippocampus [53]. It was shown that pretreatment
of the mouse hippocampus with curcumin reduced IL-
1𝛽 production, and this effect was attenuated by 5󸀠-AMP-
activated protein kinase (AMPK) inhibitor, suggesting the
possible involvement of AMPK. The authors also found
that curcumin attenuated glutamate-induced phosphoryla-
tion of PERK and IRE1𝛼; the transmembrane sensors of
ER stress that mediate inflammatory signals. Moreover,
using a neuroblastoma cell line, they showed that curcumin
inhibited glutamate-induced ROS generation, as well as
reduced glutamate-induced TXNIP expression. As a possible
molecular mechanism, they found that, in mice hippocam-
pus, glutamate stimulation increased NLRP3 expression and
the cleaved form of caspase-1 enzyme, while curcumin
attenuated NLRP3 and cleaved caspase-1 expression. The
production of IL-6, a downstream target of IL-1𝛽, was also
inhibited by curcumin treatment. In addition, curcumin
effectively attenuated mitochondrial function and prevented
caspase-3 activation in hippocampus exposed to glutamate
stimulation, effectively preventing glutamate-induced cell
apoptosis. Furthermore, in rats, curcumin administration
attenuated ischemic brain injury resulting from middle
cerebral artery occlusion (MCAO). Based on these findings,
curcumin activates AMPK that inhibits glutamate-induced
ER stress and ROS production, thus inhibiting TXNIP-
induced NLRP3 inflammasome activation and ultimately
reducing IL-1𝛽 production in mouse hippocampus limiting
brain injury.
Macrophages are popular models for the study of
NLRP3 inflammasome activation. In another study per-
formed on mouse macrophage cell line J774A.1 and peri-
toneal macrophages, curcumin was shown to strongly inhibit
IL-1𝛽 secretion triggered by LPS plus nigericin, aluminum,
ATP, or MSU [54]. Preincubation with curcumin prevented
nigericin-induced intracellular potassium level decrease,
attenuated lysosome damage and cathepsin B leakage, and
blocked high mobility group box 1 (HMGB-1) release; need-
less to say, all of these are components that may induce
NLRP3 inflammasome activation. In BMDMs, curcumin
inhibited nigericin- or aluminum crystal-induced ROS pro-
duction. The authors did not find obvious inhibitory effect
of curcumin on JNK and p38 phosphorylation enhanced
by nigericin treatment in the LPS-primed macrophages;
however, they found that ERK1/2 phosphorylation was
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Table 1: Natural compounds effecting NLRP3 inflammasome-mediated IL-1 production.
Compound Effect Mechanism Target cell Reference
Aloe vera extract Reduced IL-1𝛽
Reduced expression of NLRP3,
procaspase-1, and P2X7R
Inhibition of ERK, p38, NF𝜅B
signaling
THP-1 and human MF [51]
Aloe emodin Reduced IL-1𝛽 Reduced expression of NLRP3,procaspase-1, and ASC expression BMDM [52]
Aloe emodin Enhanced survival NLRP3-KO mice model of septicshock [52]
Curcumin Reduced IL-1𝛽 andcaspase-1 inhibition Reduced ER stress through AMPK Mouse hippocampus [53]
Curcumin Reduced ROS and TXNIP expression Neuroblastoma cells [53]
Curcumin Reduced IL-1𝛽 andcaspase-1 inhibition Lysosome protection J774A.1 [54]
Curcumin Reduced IL-1𝛽 Reduced ROS BMDM [54]
Curcumin Reduced IL-1𝛽 Reduced ROS and lysosome damageInhibition of ERK1/2 signaling
Mouse peritoneal MF of septic
shock model [54]
EGCG Reduced IL-1𝛽 andcaspase-1 inhibition
Reduced expression of NLRP3 and
procaspase-1 and Nrf2 induction
Kidney tissue from SLE mouse
model [55]
EGCG Reduced IL-1𝛽 Reduced expression of NLRP3Nrf2 induction
Rat model of contrast-induced
nephropathy [56]
Genipin Reduced IL-1𝛽 Reduced expression of NLRP3 THP-1 [57]
Genipin Reduced IL-1𝛽 andcaspase-1 inhibition
Reduced ASC oligomerization
Induced ROS and reduced autophagy
BMDM
NLRP3-KO mice [58]
Ginseng Reduced IL-1𝛽 andcaspase-1 inhibition BMDM, THP-1 [59]
Ginseng Reduced IL-1𝛽
Inhibition of iNOS and reduced NO
and ROS




Reduced expression of NLRP3
Induced AMPK phosphorylation
Reduced ROS and TXNIP expression
Endothelial cells [61]
Mangiferin Reduced IL-1𝛽
Reduced expression of NLRP3, ASC,
caspase-1, and iNOS
Nrf2 induction
Murine primary hepatocytes [62]
Propolis Reduced IL-1𝛽 Reduced ROS BMDM [63]
Quercetin Reduced IL-1𝛽 Reduced expression of NLRP3, ASC,and caspase-1
Rat model of streptozotocin-
induced diabetic nephropathy [64]
Quercetin Reduced IL-1𝛽 Reduced expression of NLRP3, ASC,and caspase-1
Rat model of fructose-induced
hyperuricemia [65]
Quercetin Reduced IL-1𝛽 andcaspase-1 inhibition
Reduced expression of NLRP3, ASC,
and caspase-1
Reduced ROS and TXNIP expression
Hepatocytes from rat model of
streptozotocin-induced diabetes [66]
Quercetin Reduced IL-1𝛽
Reduced expression of NLRP3, ASC,
and caspase-1
Reduced TXNIP expression and NF𝜅B
signaling
Hypothalamus of fructose-fed rat [67]
Quercetin Reduced IL-1𝛽
Reduced NLRP3 expression and
induced AMPK




Reduced expression of NLRP3, ASC,
and caspase-1
Reduced ROS
Rat model of spinal cord injury [69]
Mediators of Inflammation 7
Table 1: Continued.
Compound Effect Mechanism Target cell Reference
Resveratrol Reduced IL-1𝛽 Reduced NLRP3 expression andinduced Sirt1 expression Human mesenchymal stem cells [70]
Resveratrol Reduced IL-1𝛽
Reduced expression of NLRP3 and
ASC
Reduced P2X7R and COX-2
expression
Reduced ROS and p38 signaling
THP1 [71]
Resveratrol Reduced IL-1𝛽
Reduced mtDNA release and
increased cAMP
Increased p38 and JNK signaling
J774A.1 [72]
Resveratrol Reduced IL-1𝛽 Reduced NLRP3 expression andinduced Sirt1 expression Liver of high fat diet-mice [73]
Resveratrol Reduced IL-1𝛽 andcaspase-1 inhibition
Reduced mtROS
Reduced accumulation of acetylated
tubulin
BMDM
Mouse model of acute gout [50]
Resveratrol Reduced IL-1𝛽 Reduced NLRP3 expression andinduced Sirt1 expression
BV2 cells
Hippocampus of septic mice [74]
Resveratrol Reduced IL-1𝛽 Induction of autophagy and AMPKand reduced ROS
Human peritoneal mesothelial
cells [75]
Sulforaphane Reduced IL-1𝛽 andcaspase-1 inhibition
BMDM
Peritonitis mouse model of acute
gout
[28]
Sulforaphane Reduced IL-1𝛽 Reduced STAT1 signaling and inducedNrf2 translocation THP-1 [76]
Sulforaphane Reduced IL-1𝛽 andcaspase-1 inhibition
Reduced expression of NLRP3, ASC,
and caspase-1
Reduced ROS and reduced
mitochondrial dysfunction
Activation of AMPK and autophagy
Murine hepatocytes [77]
dramatically downregulated. In a mouse model of LPS-
induced septic shock, administration of curcumin signif-
icantly decreased ROS level and cathepsin B leakage in
peritoneal macrophages; additionally, peritoneal HMGB-1
and IL-1𝛽 concentrations were downregulated, resulting in
a reduced LPS-induced splenomegaly. These data suggest
that the observed reduction of secreted mature IL-1𝛽 by
curcumin is primarily attributed to the inhibition of NLRP3
inflammasome activation.
4.3. EGCG. Epigallocatechin-3-gallate (EGCG) is the major
bioactive polyphenol in green tea that has a well-documented
antioxidant activity, as it functions as a free-radical scavenger.
EGCG was reported to inhibit NF𝜅B activation and the
subsequent expression of several inflammatory molecules
such as inducible nitric oxide synthase (iNOS), matrix
metalloproteinases (MMPs), IL-6, and TNF𝛼. Besides the
anti-inflammatory role, EGCG was also thought to possess
antitumor effect [101].
In unilateral ureteral obstruction mice model, renal
inflammation has been linked to the activity of NLRP3
inflammasome and the overproduction of IL-1𝛽. Further-
more, the role of NLRP3 inflammasome was proven in a vari-
ety of human nondiabetic and chronic kidney diseases [102].
It was reported that EGCG can prevent the development of
lupus nephritis when administered to NZB/W F1 mice, the
classical model of systemic lupus erythematosus [55]. These
studies showed that EGCG treatment activated Nrf2 antiox-
idant pathway, induced the expression of Nrf2 downstream
enzymes like NAD(P)H dehydrogenase (quinone) 1 (NQO1)
and heme oxygenase 1 (HO-1), and reduced renal oxidative
stress. Furthermore, EGCG inhibited renal NLRP3 inflam-
masome activity, and the expressions of NLRP3, caspase-1,
and IL-1𝛽 were also reduced, possibly due to the EGCG-
induced attenuation of NF𝜅B pathway activity.
Very recently, the beneficial effect of EGCG was reported
in a contrast-inducednephropathy (CIN) ratmodel [56]. CIN
is a common iatrogenic cause of acute kidney injury (AKI)
after exposure to iodinated contrast medium, characterized
by oxidative stress and inflammation [103]. Similar to the
previous study, they found that EGCG treatment reduced
oxidative stress, and increased Nrf2 and HO-1 expression.
They also found that EGCG reduced the elevated IL-1𝛽
secretion and NLRP3 protein expression. The molecular
mechanisms of the observed results, however, were not
studied.
4.4. Genipin. Genipin is a water-soluble bifunctional cross-
linking reagent that was initially isolated from the Chinese
medicinal plant Gardenia jasminoides (common name jas-
mine), and it has been used for centuries as a herbal medicine
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to protect the liver and gallbladder. It possesses antihyper-
tensive, antibleeding, and antiswelling properties, in addition
to exhibiting anti-inflammatory characteristics. Chemically,
it is an aglycone, derived from an iridoid glycoside called
geniposide that is enzymatically hydrolyzed to genipin by
intestinal bacteria when administered per os [104]. Genipin
was reported to inhibit mitochondrial uncoupling protein
2 (UCP2) as well as superoxide-activated UCP2-mediated
proton leak occurring in a variety of diseases [105].
Recently, it was shown that overexpression of UCP2
caused a significant increase in NLRP3 expression in THP-
1 cells, and this was significantly inhibited by the adminis-
tration of genipin, while the levels of the adaptor protein
ASC did not change [57]. Interestingly, genipin treatment
attenuated IL-1𝛽 levels in LPS-primed cells treated with ATP;
however, this effect was not observed in cells treated with
nigericin. In addition, it was also shown that inhibition of
ATP-mediated inflammasome activation by genipin does not
alter the production of other proinflammatory cytokines such
as IL-6 and TNF𝛼.
In another recent study, in LPS-primed murine BMDMs,
genipin dramatically inhibited IL-1𝛽 secretion of LPS-primed
cells following ATP, nigericin, MSU crystals, or Listeria
monocytogenes treatment [58]. Furthermore, genipin also
inhibited the Salmonella typhimurium-induced secretion of
IL-1𝛽, which is mediated via the activation of NLRC4
inflammasome. Similar to the previous study, LPS-dependent
TNF𝛼 secretion was not impaired by genipin. Importantly,
genipin treatment did not inhibit the expression of pro-
IL-1𝛽, pro-caspase-1, or ASC proteins; however, it inhibited
NLRP3-dependent ASC oligomerization in addition to IL-1𝛽
secretion and caspase-1 activation. In contrast to its inhibitory
effect on NLRP3-mediated ASC oligomerization, genipin
did not affect NLRC4-mediated formation of ASC speckles,
whileNLRC4-mediated caspase-1 activationwas significantly
diminished. These data indicate that the inhibitory effect of
genipin on NLRC4 inflammasome activation is independent
of ASC.
4.5. Ginseng. White ginseng is the naturally dried form
of ginseng (Panax ginseng), while red ginseng is made by
steaming and drying fresh ginseng root. Red ginseng has
been used for centuries as an immune-modulator and has
also been used as an adjuvant in the treatment of infectious
and metabolic diseases. Korean red ginseng contains various
active components, including saponins such as ginsenosides
and nonsaponins such as polysaccharides, peptides, fatty
acids, and mineral oils. Ginsenosides are the major active
components of ginseng. They reduce the production of
inflammatory cytokines by inhibiting NF𝜅B signaling [106].
They also have amphiphilic nature and are able to intercalate
into the plasma membrane and influence membrane fluidity
and function.
It was shown that red ginseng extract (RGE) inhibited
ATP-, nigericin-, and aluminum-induced IL-1𝛽 secretion
in LPS-primed BMDMs and THP-1 cells and ameliorated
lethality in LPS-induced septic shock model of mice [59].
Furthermore, RGE attenuated IL-1𝛽 secretion in dsDNA-
transfected macrophages. Similar results were obtained for
ginsenosides. Furthermore, it was also shown that RGE acted
as an inhibitor of both NLRP3 and AIM2 inflammasome
activations. It was also demonstrated that RGE attenuated the
secretion of the active form of caspase-1 (p20).
It was previously reported that endogenousNOproduced
by iNOS inhibits NLRP3 inflammasome activation via the
S-nitrosylation of NLRP3 protein [107, 108]. A recent study
reported that ginsenosides negatively regulates LPS-induced
septic shock in mice by a mechanism involving inhibition
of iNOS expression and the subsequent NO production
[60]. It was shown that ginsenosides reduced NO level,
iNOS expression, and ROS level in peritoneal macrophages
and BMDMs after LPS stimulation. They also found that
ginsenoside treatment attenuated S-nitrosylation of NLRP3
protein, which resulted in increased IL-beta secretion in LPS-
activated macrophages.
4.6. Mangiferin. Mangiferin is a water-soluble, natural
polyphenol with a C-glycosylxanthone structure. The pri-
mary source of mangiferin is the mango tree (Mangifera
indica); however, it is also present in some medicinal herbs,
in Iris unguicularis, and in the honeybush, a popular herbal
tea from South Africa. It possesses a wide spectrum of
beneficial effects on health, being used as an analgesic,
antidiabetic, antisclerotic, antimicrobial, and antiviral, as well
as being praised for its anti-inflammatory effects. It has been
shown to regulate AMPK activity, and, in a recent work, it
was reported that, in human endothelial cells exposed to
high glucose, mangiferin reduced IL-1𝛽 secretion [61]. Fur-
thermore, mangiferin attenuated IRE1 phosphorylation and
reducedROS production, and it decreased TXNIP expression
and inhibited ER stress. Moreover, a decrease in NLRP3
expression and IL-1𝛽 production was also demonstrated.
Very recently, the protective role of mangiferin was
described in LPS plus D-galactosamine- (D-GalN-) induced
acute liver injury [62]. The authors showed that mangiferin
reduced IL-1𝛽 secretion and ROS production, and it also
inhibited iNOS expression but induced Nrf2 and HO-1
expression. Furthermore, it attenuated NLRP3, ASC, and
caspase-1 (p10) expression and the subsequent IL-1𝛽 produc-
tion.
4.7. Propolis. Propolis is a resinous material, produced by
bees (Apis mellifera L.) through the mixing of secretions and
enzymes from their hypopharyngeal glands with the buds
of plants and wax. A few hundred compounds have been
detected in raw propolis, including polyphenols, terpenoids,
steroids, sugar, and amino acids. Propolis composition is
largely influenced by botanical origins and geographical
location, as well as by collection season. One of the most
known biological activities of propolis is related to its anti-
inflammatory effect. Artepillin C is a simple phenol com-
posed of a single ring with two prenyl groups (3,5-diprenyl-
4-hydroxycinnamic acid) and is the major biologically active
phenolic ingredient identified in green propolis derived from
Southeast Brazil [109].
The role of artepillin C was studied on the oxidative
metabolism of PMA-stimulated RAW264.7 macrophages
[63]. It was shown that artepillin C significantly inhibited
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ROS release upon the NLRP3 activator nigericin treatment. It
was also suggested that artepillin C significantly contributed
to the modulation of chemokine-mediated inflammation, as
it significantly downregulated the release of IL-1𝛽, IL-12p40,
and TNF𝛼 by LPS + IFN𝛾-treated RAW264.7 cells, whereas
the synthesis of IL-1𝛼 and IL-6 was not affected. Besides
nigericin-mediated IL-1𝛽 production, propolis also inhibited
Legionella pneumophila-induced IL-1𝛽 cytokine secretion
in LPS-primed BMDMs. This indicates that both NLRP3
and NLRC4 inflammasome functions may be regulated by
propolis; however, further studies are required to clarify the
detailed molecular mechanism of the observed results.
4.8. Quercetin. Quercetin, a kind of flavonoid found in a
variety of vegetables, beverages, fruits, and herbs, exhibits
anti-inflammatory and antioxidant properties. Quercetinwas
reported to reduce inflammation in visceral adipose tissue,
primary human adipocytes, and the kidney of fructose-fed
rats. It was also shown to prevent diabetic kidney injury in
rats.However, themechanisms of the action of quercetinwere
not clarified.
It has been described that quercetin attenuated fructose-
induced hyperuricemia and renal dysfunction. In a study,
using streptozotocin- (STZ-) induced diabetic nephropa-
thy rat model leading to hyperuricemia and dyslipidemia,
quercetin was found to block NLRP3 inflammasome acti-
vation [64]. It was shown that the STZ-induced expres-
sion of inflammasome components was restrained, and IL-
1𝛽 secretion was reduced by quercetin treatment. Similar
results were obtained studying inflammatory responses in
fructose-induced hyperuricemia in rat [65]. They showed
that fructose significantly elevated the expression of renal
NLRP3, ASC, and caspase-1 expression, while quercetin
treatment ameliorated the expression of these proteins. Based
on their findings, it was suggested that fructose-mediated
renal NLRP3 inflammasome activation and proinflamma-
tory cytokine overproduction may be associated with the
impaired cross talk between renal JAK2-STAT3 and PPAR-𝛼
signaling pathway that in turn regulate renal inflammation.
Furthermore, it was shown that quercetin markedly
inhibited the overexpression of hepatic TXNIP, in addition
to reducing the production of ROS and the activation of
NLRP3 inflammasome, consequently resulting in decreased
IL-1𝛽 secretion [66, 110].They also showed that the decreased
caspase-1 activity downregulated the caspase-1-dependent
activation of SREBPs that are involved in fatty acid and
cholesterol synthesis. They suggested that regulation of the
TXNIP-NLRP3-SREBPs pathway by quercetin may partially
mediate the alleviation of hepatic steatosis in these diabetic
rats.
It was also shown that quercetin treatment regulated
AMPK pathway activation, glutamine-glutamate cycle dys-
function, and TXNIP overexpression; moreover, it sup-
pressed NF𝜅B pathway, eventually leading to impaired
NLRP3 inflammasome activation and IL-1𝛽 production in
the hypothalamus of high fructose- (HF-) fed rats [67].
Using human umbilical vein endothelial cells, another
group reported that quercetin suppressed palmitate- (PA-
) induced IL-1𝛽 and IL-6 induction [68]. Downregulation
of NLRP3 induction was probably partially mediated via
the inhibition of ROS production and TXNIP expression;
quercetin also inhibited IKK𝛽 activation by attenuating
its phosphorylation. Furthermore, quercetin treatment pro-
tected cells against PA insult and significantly reduced the
number of apoptotic cells. Moreover, quercetin ameliorated
ER stress-induced endothelial dysfunction through the acti-
vation of AMPK.
NLRP3 inflammasome is also recognized to have an
important role in the spinal cord tissue after traumatic spinal
cord injury (SCI), and targeting the NLRP3 inflammasome
can inhibit neuroinflammation, thereby improving func-
tional recovery in SCI rats [111].
Very recently, in a ratmodel of SCI, quercetin administra-
tion was shown to significantly improve functional recovery
[69]. Histopathological changes of the spinal cord, such as
congestion, edema, neutrophil infiltration, and structural
disruption, were inhibited by quercetin administration. To
formulate a molecular mechanism, the authors showed that
quercetin administration significantly reduced inflammatory
cytokine IL-1𝛽, IL-18, and TNF𝛼 levels; it also reduced the
NLRP3, ASC, and active caspase-1 protein expression and
ROS production. However, further studies are needed to
better characterize the mechanisms of action underlying the
beneficial effects of quercetin in inflammation and immunity.
4.9. Resveratrol. Resveratrol is a polyphenol present in
the skin of grapes and mulberry, commonly used in red
wine production. The beneficial effects of resveratrol are
thought to be mediated, in part, by its antioxidant and
anti-inflammatory properties, exhibiting beneficial effects
in several diseases [112]. Resveratrol exists as two isomers,
cis- and trans-resveratrol. The cis isomer is thought to be
produced naturally during grape fermentation as a result
of isomerization of the trans isomer by yeast isomerases.
Furthermore, cis-resveratrol can be obtained by exposure of
the trans isomer to sunlight. Several studies have shown that
trans-resveratrol exhibits a wide range of biological activities,
including anti-inflammatory, antioxidant, anticarcinogenic,
antiaging, antiplatelet aggregation, immune-modulatory, and
chemoprevention effects. However, only few studies have
been performed to examine the biological effects of the cis
isomer. Studies on cis-resveratrol have demonstrated that
it also possesses anticancer, antimicrobial, and antiplatelet
aggregation activities.
One of the biological roles of resveratrol is to initiate the
activation of sirtuin 1 (Sirt1) is a deacetylase that modifies and
inactivates inflammatory genes. At high doses, resveratrol
has been shown to activate AMPK; which is involved in
the negative regulation of the NLRP3-inflammasome [113].
It was also shown that ionizing radiation-induced IL-1𝛽
secretion by human mesenchymal stem cells (MSCs), an
effect that was effectively abrogated by pretreatment with
resveratrol [70]. Radiation-induced increase in IL-1𝛽 occurs
via the NLRP3 inflammasome activation; however, resver-
atrol treatment attenuated the expression of NLRP3. It was
also demonstrated that resveratrol treatment upregulated the
expression of Sirt1. In conclusion, it is suggested that Sirt1
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inhibits NF𝜅B transcriptional activity through deacetylation
that in turn limits the transcription of NLRP3.
In another study, it was shown that cis-resveratrol pre-
treatment significantly inhibited IL-1𝛽 secretion in THP-1 cell
culture supernatants; interestingly, cis-resveratrol induced
IL-18 secretion under these conditions [71]. Accordingly, cis-
resveratrol significantly reduced IL-1𝛽 mRNA expression;
in contrast, cis-resveratrol used at the same concentra-
tion increased IL-18 mRNA expression. Furthermore, cis-
resveratrol increased the mRNA and protein levels of NLRP1
and NLRP3, indicating that the inhibitory effect of cis-
resveratrol on IL-1𝛽 secretion is not due to the down-
regulation of NLRP1, NLRP3, or ASC expression. Similar
results were obtained on LPS-primed J774A.1 macrophages
where resveratrol inhibited the ATP-induced IL-1𝛽 secretion;
however, in this study, the authors did not find changes in the
expression of NLRP3 [72], showing that the resveratrol did
not inhibit the priming signal of NLRP3.
Huang et al. suggested that the inhibitory effect of cis-
resveratrol on IL-1𝛽 secretion may be due to the reduced
expression of purinergic receptor P2X7R and the ER stress
marker GRP78, which leads to suppression of ROS pro-
duction and reduced caspase-1 and caspase-4 activation. It
was found that cis-resveratrol also inhibited cyclooxygenase-
(COX-) 2 expression, which may be responsible for the
observed decrease of PGE2 production. Furthermore, inhi-
bition of pro-IL-1𝛽 and COX-2 expression may occur by
downregulating the activation of the p38 MAPK path-
way [71]. Importantly, in contrast to these observations,
increased phosphorylation of p38 was detected in ATP-
activated J774A.1 macrophages by Chang et al., while it
did not significantly increase the phosphorylation levels
of ERK1/2, and it reduced the phosphorylation levels of
JNK1/2. The levels of mtDNA release into the cytosol were
significantly reduced by resveratrol, indicating that there
was less mitochondrial injury in resveratrol-treated cells
[72] Furthermore, the authors also showed that resveratrol
increased cellular cAMP level in J774A.1 macrophages, which
acts as a negative regulator of inflammatory responses and
inhibits NLRP3 inflammasome activation.
The effect of resveratrol on NLRP3 inflammasome was
further proved by a study showing that four weeks of
resveratrol administration inhibited the expression of NLRP3
inflammasome components, IL-1, IL-6, and TNF𝛼, and in
livers of HF-fed mice [73]. They also showed that the
regulatory effects of resveratrol on NLRP3 inflammasome
may come about through the combined effects of Sirt1 and
Sirt6.
In a recent study [50], it was found that resveratrol
treatment successfully suppressed the maturation of both
IL-1𝛽 and caspase-1 in response to Pam3CSK4; a TLR1/2
agonist, plus various inducers (like nigericin, ATP, MSU,
and silica) of the NLRP3-inflammasome. In mouse BMDMs,
however, it did not affect the production of IL-1𝛽 medi-
ated by the NLRC4-inflammasome (flagellin) or the AIM2-
inflammasome (dsDNA). On a mouse model of acute gout,
they indicated that resveratrol reduced the amount of mature
IL-1𝛽 and the subsequent recruitment of neutrophils into
the peritoneal cavities of mice after challenge with MSU
crystals. These findings indicate that resveratrol suppresses
the activation of the NLRP3-inflammasome both in vitro
and in vivo. As a possible mechanism, they showed that
resveratrol at a substantially higher dosage successfully
suppressed mitochondrial ROS production. Furthermore,
resveratrol treatment prevented the accumulation of acety-
lated 𝛼-tubulin; thus,inhibiting the proximate localization of
ASC and NLRP3 in macrophages.
In a very recent publication [74], the authors showed that
resveratrol preventedATP-inducedNLRP3 activation and IL-
1𝛽 production in the BV2 cell line and in septic mice as well.
They also found that resveratrol treatment reduced NLRP3
and IL-1𝛽 expression in the hippocampus of the mice, and
they suggested that the protecting effect of resveratrol was
mediated via the increased expression of Sirt1 in BV2 cells.
Another recent publication found that glucose-based
peritoneal dialysis increased mitochondrial ROS production
and subsequent IL-1𝛽 secretion through NLRP3 inflamma-
some in human peritoneal mesothelial cells (HPMC). As
a mechanism for its action, they showed that resveratrol
induced mitophagy/autophagy of the cells via AMPK activa-
tion and protected cells fromROS-inducedNLRP3-mediated
inflammatory injury [75].
4.10. Sulforaphane. Sulforaphane (SFN) is a natural com-
pound present in cruciferous vegetables such as broccoli,
cabbage, Brussel sprouts, mustard, and radish. Chemically,
SFN is an isothiocyanate that is known to react with
sulfhydryl groups and tomodify proteins at cysteine residues.
Sulforaphane is produced from the precursor glucoraphanin
by the enzymatic activity of myrosinase, when the cell walls
of the plant are damaged, for example, during chewing.
SFN has been known as a cytoprotective agent for cancer
prevention or treatment, and it also has an important role
in cardiovascular, neurologic, and other diseases (reviewed
in [114]). SFN is a known inducer of the Nrf2 antioxidant
pathway, as it activates the Nrf2 transcription factor by
reacting with cysteine residues of its repressor, Keap1 [115].
In addition, it also inhibits NF𝜅B signaling [116].
It was shown that SFN inhibited IL-1𝛽 processing by
NLRP1-, NLRP3-, NLRC4-, and AIM2- inflammasome com-
plexes in mouse BMDMs [28]. It was also demonstrated
that SFN inhibits the inflammasome in an Nrf2-independent
manner, as SFN-mediated inhibition of NLRP3- andNLRC4-
dependent IL-1𝛽 processing and secretion was not reversed
in Nrf2-knockout BMDMs. When SFN was added directly
to the cell lysates, it did not inhibit IL-1𝛽 processing,
demonstrating that SFN does not directly inhibit the protease
activity of caspase-1. The authors found that SFN-mediated
inhibition of the inflammasomes is not affected by ROS
modulation, and neither proteasome-dependent proteolysis
nor de novo protein synthesis is required for SFN-mediated
inhibition of the inflammasomes. In a peritonitis model of
acute gout, SFN treatment significantly reducedMSU crystal-
induced IL-1𝛽 production, demonstrating that SFN inhibits
the NLRP3 inflammasome function in vivo. Nonetheless,
the authors concluded that SFN inhibits multiple inflam-
masomes in vitro and in vivo by a mechanism independent
































































Figure 3: Molecular targets of natural compounds affecting NLRP3 inflammasome-mediated IL-1 production.
of inflammasome priming and Nrf2 signaling; however, the
exact molecular mechanism was not explored.
As SFN is able to penetrate the blood-brain barrier
[117], it gained a considerable attention as a candidate
for Alzheimer’s disease (AD) therapy. SFN was shown to
protect the brain from A𝛽-induced oxidative cell death via
activation of Nrf2 signaling cascade [118]. As A𝛽 fibrils
have been shown to activate NLRP3 inflammasome, the
question arose whether SFN may regulate this mechanism.
In a very recent study, it was shown that SFN significantly
downregulated IL-1𝛽 production and NLRP3 expression in
A𝛽1–42 peptide-stimulated human THP-1 cells macrophages
[76]. It was found that A𝛽1–42 peptide-induced STAT-1
phosphorylation was significantly attenuated by SFN. The
authors showed that SFN inducedNrf2 nuclear translocation,
which was subsequently accompanied by an increase in HO-
1 protein levels. Furthermore, A𝛽1–42 peptide-induced IL-
1𝛽 production was diminished by siRNA-mediated knock-
down of Nrf2 or HO-1. They also found that the increased
proinflammatory miRNA-146a level following A𝛽1–42 treat-
ment was significantly attenuated by SFN, whereas miRNA-
125b and miRNA-155 levels were not changed. These are
specific proinflammatory miRNAs that were reported to be
increased in both the extracellular fluid and cerebrospinal
fluid of AD patients. In conclusion, SFN can suppress A𝛽1–
42-induced caspase-1-dependent inflammasome activation,
possibly through inhibiting STAT-1 phosphorylation and
activation of the Nrf2/HO-1 signaling pathway.
Also very recently, another research group reported that
oral administrations of SFN suppressed the saturated fatty
acid-induced NLRP3 inflammasome activation in the liver
of mice [77]. They found that SFN decreased the expression
of ASC, caspase-1, and IL-1𝛽 levels; additionally, it inhibited
the activity of caspase-1 enzyme in primary hepatocytes. It
was also shown that SFN reduced the palmitate-induced
ROS production by the mitochondria, implying that SFN
prevented mitochondrial dysfunction, and this protecting
mechanism was in part mediated by the activation of AMPK.
They concluded that activation of AMPK and autophagy by
SFN could protect from mitochondrial dysfunction induced
by saturated fatty acids, resulting in a downregulation of fat-
induced activation of the NLRP3 inflammasome.
5. NLRP3 Inflammasome and the
Xenohormesis Hypothesis
As it was described in detail above, polyphenols like resvera-
trol, curcumin, EGCG, and quercetin are potent inhibitors of
NLRP3 inflammasome-mediated IL-1𝛽 production, typically
acting at more than one element of the involved pathways
(Figure 3).However, it should be noted that these polyphenols
have an evenmuch broader biological effect, as they influence
a variety of pathways [119], though not all are directly
connected to the function of the NLRP3 inflammasome.
Importantly, more than 8000 natural polyphenols have been
described [120], providing a large library of compounds as
potential inflammasome inhibitors. Many of these polyphe-
nols (such as resveratrol and curcumin) are overproduced
by stressed plants, triggering pathways mimicking the effect
of caloric restriction. It has been proposed that organisms,
from yeast to humans, consuming stressed plants could
interpret the stress signal carried by such polyphenols as a
potential risk of future limitation of food availability, and, in
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turn, adapting for the pursuit of longevity, a theory termed
as Xenohormesis [121–123]. Interestingly, the structurally
unrelated resveratrol and curcumin can achieve this caloric
restriction mimicking effect by activating AMPK and Sirt1
[124]. However, polyphenols are also known to have an
antioxidant effect, activate glutathione S-transferases, and
inhibit COX enzymes among many other effects [125, 126].
Interestingly, one of the most frequently used COX inhibitor
is aspirin, a derivative of another stress-induced phytochem-
ical, salicylic acid.
A major concern of polyphenol use in therapy is the
bioavailability of these compounds. Nevertheless, typical
dietary polyphenol intake is about 14mg/kg/day, which is
within the range of providing biologically active doses [127].
6. Concluding Remarks
Most of the time, inflammasome-mediated IL-1𝛽 production
or caspase-mediated pyroptosis is beneficial for the host, as it
protects from infection or prevents further damage.However,
prolonged cytokine production, as in the case of sterile
inflammation caused by endogenous danger signals, may
lead to the development of autoinflammatory or metabolic
diseases. Chronic inflammation compromises the host’s life
quality and requires sustained pharmacological and surgical
treatments. The paradigm of drug discovery in Western
medicine is to develop highly selective compounds against
individual druggable targets. Currently, the main treatment
methods for these patients are targeting IL-1𝛽. However,
prolonged usage of drugs may induce different side effects;
furthermore, some form of medications are very expensive,
which limits their widespread use.
Besides the high expenses, another drawback of tradi-
tional drug design is that many of the promising compounds
fail in the early or later stages of drug development. Tradi-
tional medicine uses many plant products to treat diseases;
however, the exact mechanisms behind their use is still
mostly lacking, partially as a consequence of the pleiotropic
effect of the active compounds, as detailed in this review.
Nevertheless, clarification of the molecular mechanism of
action of such natural compounds, already used in traditional
medicine for quite some time, will undoubtedly aid in the
production of safe and cheap candidate medications to be
used in the treatment of diseases, including those appearing
as a consequence of NLRP3 inflammasome-mediated IL-1𝛽
overproduction.
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